SOCS1: phosphorylation, dimerization and tumor suppression
| Autor: | Frédéric Lessard, Lian Mignacca, Gerardo Ferbeyre, Emmanuelle Saint-Germain |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Cancer Research
medicine.medical_treatment cytokine singling SH2 domain law.invention 03 medical and health sciences 0302 clinical medicine law medicine SOCS3 030304 developmental biology 0303 health sciences P53 Chemistry Suppressor of cytokine signaling 1 SH2 domains 3. Good health Cell biology Dasatinib Cytokine Oncology 030220 oncology & carcinogenesis Research Perspective Suppressor Phosphorylation Tyrosine kinase medicine.drug SRC kinases |
| Zdroj: | Oncoscience |
| ISSN: | 2331-4737 |
| Popis: | Suppressor of cytokine signaling (SOCS) family members are upregulated following JAK-STAT pathway activation by cytokines. SOCS proteins are recognized inhibitors of cytokine signaling playing roles in cell growth and differentiation. Moreover, SOCS1 and SOCS3 have been shown to be involved in tumor suppression through their ability to interact with p53 leading to the activation of its transcriptional program and showing the implication of SOCS family members in the regulation of apoptosis, ferroptosis and senescence. More recently, we demonstrated that the SRC family of non-receptor tyrosine kinases (SFK) can phosphorylate SOCS1 leading to its homodimerization and inhibiting its interaction with p53. Then, we reactivated the SOCS1-p53 tumor suppressor axis with the SFK inhibitor dasatinib in combination with the p53 activating compound PRIMA. This work suggests new avenues for cancer treatment and leaves open several new questions that deserve to be addressed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|